Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
The role of T cell apoptosis in nervous system autoimmunity.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
Food and Drug Administration drug insert for Campath (alemtuzumab)
Fingolimod Impedes Schwann Cell-Mediated Myelination: Implications for the Treatment of Immune Neuropathies?Effect of Fingolimod on Schwann Cells.
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.
Architecture of human mTOR complex 1.
Glatiramer acetate during early pregnancy: A prospective cohort study.
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne Muscular Dystrophy
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.

Pages